Loading

Longevity Therapeutics Enter Biopharma Mainstream

June 03, 2024
Breakout Session
Next Generation Biotherapeutics
23BC
This session will focus on the longevity and maturing of the therapeutics field, growing interest in biopharma by investors in the diseases of aging framework and approaches, and shift from the aspirational preventative approaches to more pragmatic disease-based drug development and tractable clinical trial designs. Additionally, panelists will discuss the evolution across key geographies, with respect to therapeutic areas and across modalities.
Speakers
Brian Gormley
Reporter
Wall Street Journal
Speakers
Simone Fantaccini, MD, MBA
Chief Scientific Officer & Head of Medical Affairs
Novartis
Cristina Ghenoiu, PhD
Investor
Mubadala Capital
Robert Gould, PhD
Operating Partner
Khosla Ventures
Marco Quarta, PhD
Founder and CEO
Rubedo Life Sciences
Hanadie Yousef, PhD
Chief Executive Officer and Co-Founder
Juvena Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS